Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Cough can occur with many signs and symptoms which include stuffy nose, hoarseness, wheezing and shortness of breath, and heartburn or a sour taste in the mouth. The treatment for cough entails antihistamines, decongestants, antibiotics, and cough suppressants.

The Cough pipeline market research report provides an overview of the Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Cough Pipeline Drugs Market by Key Targets

Some of the key targets of the Cough pipeline drugs market are P2X Purinoceptor 3), Glutamate Receptor Ionotropic NMDA 1, Glutamate Receptor Ionotropic NMDA 2B, Mu Type Opioid Receptor, Sodium Channel, Bifunctional Epoxide Hydrolase 2, Kappa Type Opioid Receptor, P2X Purinoceptor 4), Sodium Channel Protein Type 10 Subunit Alpha, and Sodium Channel Protein Type 9 Subunit Alpha.

Cough Pipeline Drugs Market, by Targets

Cough Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Cough Pipeline Drugs Market

Some of the key mechanisms of action of the Cough pipeline drugs market are P2X Purinoceptor 3 Antagonist, Glutamate Receptor Ionotropic NMDA 1 Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, Sodium Channel Blocker, Bifunctional Epoxide Hydrolase 2 Inhibitor, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, P2X Purinoceptor 4 Antagonist, and Sodium Channel Protein Type 10 Subunit Alpha Blocker.

Cough Pipeline Drugs Market, by Mechanisms of Action

Cough Pipeline Drugs Market, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Cough Pipeline Drugs Market

The routes of administration in the Cough pipeline drugs market are oral, inhalational, intravenous, and topical.

Cough Pipeline Drugs Market, by Routes of Administration

Cough Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Cough Pipeline Drugs Market

The molecule types in the Cough pipeline drugs market are small molecule and peptide. Small Molecule has the highest pipeline products.

Cough Pipeline Drugs Market, by Molecule Types

Cough Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Cough Pipeline Drugs Market Companies

Some of the key companies in the Cough pipeline drugs market are Merck & Co Inc, Tris Pharma Inc, Wuhan LL Science and Technology Development Co Ltd, Adare Pharma Solutions, Algernon Pharmaceuticals Inc, Korea United Pharm Inc, Nocion Therapeutics Inc, SiteOne Therapeutics Inc, AfaSci Inc, and Aldeyra Therapeutics Inc.

Cough Pipeline Drugs Market, by Key Companies

Cough Pipeline Drugs Market, by Key Companies

To know more about key companies, download a free report sample

Market Report Overview

Key Targets P2X Purinoceptor 3), Glutamate Receptor Ionotropic NMDA 1, Glutamate Receptor Ionotropic NMDA 2B, Mu Type Opioid Receptor, Sodium Channel, Bifunctional Epoxide Hydrolase 2, Kappa Type Opioid Receptor, P2X Purinoceptor 4), Sodium Channel Protein Type 10 Subunit Alpha, and Sodium Channel Protein Type 9 Subunit Alpha
Key Mechanisms of Action P2X Purinoceptor 3 Antagonist, Glutamate Receptor Ionotropic NMDA 1 Antagonist, Glutamate Receptor Ionotropic NMDA 2B Antagonist, Sodium Channel Blocker, Bifunctional Epoxide Hydrolase 2 Inhibitor, Kappa Type Opioid Receptor Agonist, Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, P2X Purinoceptor 4 Antagonist, and Sodium Channel Protein Type 10 Subunit Alpha Blocker
Key Routes of Administration Oral, Inhalational, Intravenous, and Topical
Key Molecule Types Small Molecule and Peptide
Key Companies Merck & Co Inc, Tris Pharma Inc, Wuhan LL Science and Technology Development Co Ltd, Adare Pharma Solutions, Algernon Pharmaceuticals Inc, Korea United Pharm Inc, Nocion Therapeutics Inc, SiteOne Therapeutics Inc, AfaSci Inc, and Aldeyra Therapeutics Inc

Scope 

This report provides:

  • A snapshot of the global therapeutic landscape of Cough (Respiratory).
  • Reviews of pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • Evaluation of Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Cough (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Adare Pharma Solutions
AfaSci Inc
Aldeyra Therapeutics Inc
Algernon Pharmaceuticals Inc
Antheia Inc
Asana BioSciences LLC
Axalbion SA
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Conrig Pharma ApS
Evotec SE
Future Analgesics
Grunenthal GmbH
Hyundai Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Korea United Pharm Inc
Merck & Co Inc
NeRRe Therapeutics Ltd
Nippon Chemiphar Co Ltd
Nocion Therapeutics Inc
Nuformix Plc
PhytoHealth Corp
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
SiteOne Therapeutics Inc
SolAeroMed Inc
Trevi Therapeutics Inc
Tris Pharma Inc
Whan In Pharm Co Ltd
Wuhan LL Science and Technology Development Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough – Overview

Cough – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough – Companies Involved in Therapeutics Development

Cough – Drug Profiles

Cough – Dormant Projects

Cough – Discontinued Products

Cough – Product Development Milestones

Featured News & Press Releases

Mar 29, 2022: Aldeyra Therapeutics to announce top-line data for systemic RASP modulator ADX-629 at 2022 Research & Development Day

Mar 22, 2022: Trevi Therapeutics hosting key opinion leader webinar on the seriousness of chronic cough in Idiopathic Pulmonary Fibrosis (IPF)

Mar 16, 2022: Trevi ends enrolment early in Phase II IPF chronic cough trial after positive interim data

Feb 24, 2022: Trevi Therapeutics reports statistically significant result on interim analysis from the Ph2 CANAL trial of Nalbuphine ER in the treatment of chronic cough in idiopathic pulmonary fibrosis

Feb 04, 2022: Algernon Pharmaceuticals announces completion of enrollment in its Phase 2 study of Ifenprodil for IPF and chronic cough

Jan 24, 2022: Merck provides U.S. and Japan regulatory update for Gefapixant

Jan 20, 2022: MSD obtained manufacturing and marketing approval for Rifunua tablets, the world’s first selective P2X3 receptor antagonist for chronic cough.

Jan 17, 2022: Algernon receives positive FDA feedback on Phase IIb chronic cough trial

Dec 28, 2021: Hansoh Pharmaceutical Group Company announces clinical trial notice of HS-10383 tablets

Dec 21, 2021: Sino Biopharmaceutical : Innovative medicine “TCR1672” obtained approval for clinical trial

Dec 13, 2021: BELLUS Health announces positive topline results from its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough

Dec 02, 2021: Algernon Pharmaceuticals projects full enrollment for phase 2 IPF and chronic cough trial

Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937

Oct 21, 2021: Axalbion treats first subjects in phase II chronic cough treatment trial

Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Cough, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cough – Pipeline by Adare Pharma Solutions, 2022

Cough – Pipeline by AfaSci Inc, 2022

Cough – Pipeline by Aldeyra Therapeutics Inc, 2022

Cough – Pipeline by Algernon Pharmaceuticals Inc, 2022

Cough – Pipeline by Antheia Inc, 2022

Cough – Pipeline by Asana BioSciences LLC, 2022

Cough – Pipeline by Axalbion SA, 2022

Cough – Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022

Cough – Pipeline by BELLUS Health Inc, 2022

Cough – Pipeline by Charleston Laboratories Inc, 2022

Cough – Pipeline by Chiesi Farmaceutici SpA, 2022

Cough – Pipeline by Conrig Pharma ApS, 2022

Cough – Pipeline by Evotec SE, 2022

Cough – Pipeline by Future Analgesics, 2022

Cough – Pipeline by Grunenthal GmbH, 2022

Cough – Pipeline by Hyundai Pharma Co Ltd, 2022

Cough – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022

Cough – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Cough – Pipeline by Korea United Pharm Inc, 2022

Cough – Pipeline by Merck & Co Inc, 2022

Cough – Pipeline by NeRRe Therapeutics Ltd, 2022

Cough – Pipeline by Nippon Chemiphar Co Ltd, 2022

Cough – Pipeline by Nocion Therapeutics Inc, 2022

Cough – Pipeline by Nuformix Plc, 2022

Cough – Pipeline by PhytoHealth Corp, 2022

Cough – Pipeline by Shionogi & Co Ltd, 2022

Cough – Pipeline by Sino Biopharmaceutical Ltd, 2022

Cough – Pipeline by SiteOne Therapeutics Inc, 2022

Cough – Pipeline by SolAeroMed Inc, 2022

Cough – Pipeline by Trevi Therapeutics Inc, 2022

Cough – Pipeline by Tris Pharma Inc, 2022

Cough – Pipeline by Whan In Pharm Co Ltd, 2022

Cough – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022

Cough – Dormant Projects, 2022

Cough – Dormant Projects, 2022 (Contd..1)

Cough – Dormant Projects, 2022 (Contd..2)

Cough – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Cough, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.